Provided by Tiger Trade Technology Pte. Ltd.

Cellectar Biosciences

2.70
-0.2000-6.90%
Post-market: 2.700.00000.00%19:12 EDT
Volume:31.45K
Turnover:88.11K
Market Cap:11.45M
PE:-0.32
High:2.87
Open:2.87
Low:2.70
Close:2.90
52wk High:20.59
52wk Low:2.45
Shares:4.24M
Float Shares:4.06M
Volume Ratio:1.15
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.3544
EPS(LYR):-8.3544
ROE:-170.27%
ROA:-71.01%
PB:1.43
PE(LYR):-0.32

Loading ...

EMA news ‘a substantial positive catalyst’ for Cellectar, says Oppenheimer

TIPRANKS
·
Oct 06, 2025

BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer

Reuters
·
Oct 06, 2025

Cellectar Biosciences : Potential 2027 European Approval and Commercial Launch of Iopofosine I 131 as a Treatment for Refractory (Post-Btki) Wm

THOMSON REUTERS
·
Oct 06, 2025

Cellectar Biosciences Inc - Cma Application for Iopofosine I 131 Expected in Early 2026

THOMSON REUTERS
·
Oct 06, 2025

Cellectar Biosciences Announces European Medicines Agency (Ema) Confirms Eligibility to File for Conditional Marketing Authorization (Cma) for Iopofosine I 131 as a Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm)

THOMSON REUTERS
·
Oct 06, 2025

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

GlobeNewswire
·
Oct 06, 2025

Oppenheimer Remains a Hold on Cellectar Biosciences (CLRB)

TIPRANKS
·
Oct 02, 2025

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

GlobeNewswire
·
Sep 30, 2025

Cellectar, Evestia entered into agreement for Phase 1b study of CLR 125

TIPRANKS
·
Sep 24, 2025

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)

GlobeNewswire
·
Sep 24, 2025